HUT68689A - Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions - Google Patents
Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositionsInfo
- Publication number
- HUT68689A HUT68689A HU9401679A HU9401679A HUT68689A HU T68689 A HUT68689 A HU T68689A HU 9401679 A HU9401679 A HU 9401679A HU 9401679 A HU9401679 A HU 9401679A HU T68689 A HUT68689 A HU T68689A
- Authority
- HU
- Hungary
- Prior art keywords
- heteroaryloxymethyl
- interleukin
- ketones
- alpha
- producing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
- C07D311/46—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
- C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7162393A | 1993-06-03 | 1993-06-03 | |
US23792094A | 1994-04-29 | 1994-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
HU9401679D0 HU9401679D0 (en) | 1994-09-28 |
HUT68689A true HUT68689A (en) | 1995-07-28 |
Family
ID=26752445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9401679A HUT68689A (en) | 1993-06-03 | 1994-06-03 | Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions |
Country Status (13)
Country | Link |
---|---|
US (2) | US5585357A (hu) |
EP (1) | EP0644198A1 (hu) |
JP (1) | JPH0789951A (hu) |
KR (1) | KR950000694A (hu) |
AU (1) | AU690102B2 (hu) |
CA (1) | CA2125021A1 (hu) |
CZ (1) | CZ135594A3 (hu) |
FI (1) | FI942624A (hu) |
HU (1) | HUT68689A (hu) |
IL (1) | IL109867A (hu) |
NO (1) | NO942064L (hu) |
NZ (1) | NZ260669A (hu) |
SK (1) | SK67394A3 (hu) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6008217A (en) * | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
US5714484A (en) * | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
US5756466A (en) * | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) * | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) * | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5863902A (en) * | 1995-01-06 | 1999-01-26 | Sibia Neurosciences, Inc. | Methods of treating neurodegenerative disorders using protease inhibitors |
AU5122196A (en) * | 1995-03-31 | 1996-10-16 | Takeda Chemical Industries Ltd. | Cysteine protease inhibitor |
EP0761680A3 (en) * | 1995-09-12 | 1999-05-06 | Ono Pharmaceutical Co., Ltd. | Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity |
US5843904A (en) * | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
EP0900791A1 (en) | 1995-12-27 | 1999-03-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
US6416753B1 (en) | 1996-03-15 | 2002-07-09 | The General Hospital Corporation | Method for modulating apoptosis |
US5919790A (en) * | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
BR9814817A (pt) * | 1997-10-10 | 2002-01-08 | Cytovia Inc | Inibidores de apoptose de dipeptìdio e o uso dos mesmos |
IL122770A0 (en) | 1997-12-25 | 1998-08-16 | Gotit Ltd | Automatic spray dispenser |
ES2244178T3 (es) | 1998-03-09 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | Derivados de 1,2-diazepan como inhibidores de la enzima convertidora de interleuquina-1 beta. |
EP1076563B1 (en) * | 1998-03-16 | 2005-05-11 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
EP2261232A3 (en) | 1998-03-19 | 2011-04-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
CA2327185A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
US7157430B2 (en) * | 1998-10-22 | 2007-01-02 | Idun Pharmaceuticals, Inc. | (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases |
EP1159273A1 (en) | 1999-03-02 | 2001-12-05 | Boehringer Ingelheim Pharmaceuticals Inc. | Compounds useful as reversible inhibitors of cathepsin s |
ATE336480T1 (de) * | 1999-03-16 | 2006-09-15 | Cytovia Inc | Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung |
CN1176941C (zh) | 1999-04-09 | 2004-11-24 | 西托维亚公司 | Caspase抑制剂及其应用 |
CN1235875C (zh) | 1999-08-27 | 2006-01-11 | 西托维亚公司 | 取代的α-羟基酸天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
GB9922830D0 (en) | 1999-09-27 | 1999-11-24 | Novartis Ag | Processes |
US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
IL134219A0 (en) * | 2000-01-25 | 2001-04-30 | Gotit Ltd | Spray dispenser |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
AU2001293533A1 (en) | 2000-09-08 | 2002-03-22 | Merck Frosst Canada & Co. | Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
US6800619B2 (en) * | 2000-09-13 | 2004-10-05 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
FR2815541B1 (fr) * | 2000-10-24 | 2008-02-29 | Lipha | Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique |
AU2003211052A1 (en) * | 2002-02-11 | 2003-09-04 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
JP2005536462A (ja) | 2002-04-30 | 2005-12-02 | ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド | カスパーゼ−3阻害剤としてのキノリン誘導体、この製造方法及びこれを含む薬剤学的組成物 |
CA2450643A1 (en) * | 2002-12-24 | 2004-04-30 | Northern Therapeutics Inc. | Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension |
CN102362867A (zh) * | 2004-05-15 | 2012-02-29 | 沃泰克斯药物股份有限公司 | 使用ice抑制剂治疗癫痫发作 |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
EP1778221A2 (en) | 2004-05-27 | 2007-05-02 | Vertex Pharmaceuticals Incorporated | Ice inhibitors for the treatment of autoinflammatory diseases |
CA2657660A1 (en) * | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
US8563754B2 (en) * | 2010-01-28 | 2013-10-22 | New York University | Compounds, compositions and methods for preventing skin darkening |
PE20141637A1 (es) | 2011-04-28 | 2014-11-20 | Japan Tobacco Inc | Compuesto de amida y aplicacion farmaceutica para el mismo |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
WO2023283256A1 (en) | 2021-07-09 | 2023-01-12 | Aligos Therapeutics, Inc. | Anti-viral compounds |
WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5055451A (en) * | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
WO1991015577A1 (en) * | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
DE69226820T2 (de) * | 1991-06-21 | 1999-05-12 | Merck & Co., Inc., Rahway, N.J. | Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen |
AU657701B2 (en) * | 1991-08-30 | 1995-03-23 | Vertex Pharmaceuticals Incorporated | Interleukin 1beta protease and interleukin 1beta protease inhibitors |
GB9123326D0 (en) * | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
ATE169224T1 (de) * | 1992-02-21 | 1998-08-15 | Merck & Co Inc | Peptidylderivate und inhibitoren des interleukin- 1-g(b)-konvertierenden enzyms |
-
1994
- 1994-06-01 JP JP6119873A patent/JPH0789951A/ja active Pending
- 1994-06-02 IL IL10986794A patent/IL109867A/en not_active IP Right Cessation
- 1994-06-02 CA CA002125021A patent/CA2125021A1/en not_active Abandoned
- 1994-06-02 AU AU63473/94A patent/AU690102B2/en not_active Ceased
- 1994-06-02 NZ NZ260669A patent/NZ260669A/en not_active IP Right Cessation
- 1994-06-02 SK SK673-94A patent/SK67394A3/sk unknown
- 1994-06-02 CZ CZ941355A patent/CZ135594A3/cs unknown
- 1994-06-02 EP EP94201571A patent/EP0644198A1/en not_active Withdrawn
- 1994-06-03 HU HU9401679A patent/HUT68689A/hu unknown
- 1994-06-03 FI FI942624A patent/FI942624A/fi unknown
- 1994-06-03 NO NO942064A patent/NO942064L/no not_active Application Discontinuation
- 1994-06-03 KR KR1019940012529A patent/KR950000694A/ko not_active Application Discontinuation
-
1996
- 1996-01-29 US US08/593,773 patent/US5585357A/en not_active Expired - Lifetime
- 1996-10-16 US US08/732,173 patent/US5677283A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
HU9401679D0 (en) | 1994-09-28 |
FI942624A0 (fi) | 1994-06-03 |
IL109867A0 (en) | 1994-10-07 |
US5677283A (en) | 1997-10-14 |
KR950000694A (ko) | 1995-01-03 |
AU6347394A (en) | 1995-04-27 |
JPH0789951A (ja) | 1995-04-04 |
EP0644198A1 (en) | 1995-03-22 |
AU690102B2 (en) | 1998-04-23 |
IL109867A (en) | 1998-07-15 |
NO942064D0 (no) | 1994-06-03 |
NZ260669A (en) | 1995-12-21 |
NO942064L (no) | 1994-12-05 |
CA2125021A1 (en) | 1994-12-04 |
FI942624A (fi) | 1994-12-04 |
US5585357A (en) | 1996-12-17 |
SK67394A3 (en) | 1995-07-11 |
CZ135594A3 (en) | 1994-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT68689A (en) | Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions | |
HU9402232D0 (en) | 1-benzene-sulfonyl-1,3-dihydro-indol-2-one derivatives, process for producing them and pharmaceutical compositions containing them | |
HUP9802565A3 (en) | N-benzyl-dioxothiazolidinylmethyl-benzamide derivatives, pharmaceutical compositions containing them and process for producing the same | |
HUT70848A (en) | 1-aminoethyl-indol derivatives, process for production thereof and pharmaceutical compositions comprising them | |
HU9402238D0 (en) | 1-benzenesulfonyl-1,3-dihydro-2h-benzimidazol-2-one derivatives, process for producing them and pharmaceutical compositions containing them | |
AU4048299A (en) | Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same | |
AU6373094A (en) | Enzyme-containing pharmaceutical or cosmetic composition, process for preparing the same and its use | |
HUP9603433A3 (en) | 4-6-diaryl-pyrimidine-derivatives, process for producing them and pharmaceutical compositions containing them | |
HUT76065A (en) | Indole derivatives, pharmaceutical compositions containing them, process for producing them and their use | |
HUP9901739A3 (en) | Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them | |
HUP9601358A3 (en) | Fluoro-phenyl-substituted alkenyl-carboxylic-guanidines, process for producing them, their use as medicines or diagnostica, and pharmaceutical compositions containing them | |
HU9601321D0 (en) | Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, their use as pharmaceutical compositions or diagnostica, and pharmaceutical compositions containing them | |
HUT67142A (en) | Spirostanil glycosidal cristalline monohydrate, pharmaceutical compositions containing the same and process for their production | |
HUP9602640A3 (en) | Substituted benzoyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them and the use of the compds. | |
GR3021203T3 (en) | Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane. | |
HU9400934D0 (en) | Thiadiazinone derivatives, pharmaceutical compositions containing them and process for producing them | |
HUP9602763A3 (en) | 3-phenyl isoxazole derivatives, process for producing them and pharmaceutical compositions containing the same | |
EP0622384A3 (de) | Verfahren zur Herstellung von Polymerpolyesterolen. | |
EP0628536A3 (de) | Verfahren zur Herstellung von Aminen. | |
HUT68320A (en) | Fluorinated 4-amino-androstadiene-derivatives, pharmaceutical composition containing the same and process for producing them | |
HUP9601331A3 (en) | Piperazine- and homopiperazine-derivatives, process for producing them and pharmaceutical compositions containing them | |
HU9503932D0 (en) | Substituted benzol-sulfonyl-ureas and-thioureas, pharmaceutical compositions containing them and process for producing them | |
EP0635482A3 (de) | Verfahren zur Herstellung von mehrfach fluorierten Nitrobenzolen. | |
AU2792195A (en) | Chondramides, production methods, compositions comprising chondramides and cultures for chondramide production | |
EP0444605A3 (en) | Angiotensin converting enzyme inhibitor, method for preparing it, composition containing the same and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DGB9 | Succession in title of applicant |
Owner name: SANOFI, FR |
|
DGB9 | Succession in title of applicant |
Owner name: VERTEX PHARMACEUTICALS INCORPORATED, US |
|
DFC4 | Cancellation of temporary protection due to refusal |